The present invention relates to the technical field of medicine and relates to an instant release pharmaceutical preparation of an anticoagulant and a preparation method therefor. The instant release pharmaceutical preparation of an anticoagulant comprises a vicagrel compound or a pharmaceutically acceptable form thereof, the preparation is a tablet or a capsule, the vicagrel or the pharmaceutically acceptable form thereof is provided at a suitable particle size, and the D90 thereof <50 μm. With regard to the drug-containing particles obtained by the present invention, a pharmaceutical preparation formed therefrom exhibits rapid release characteristics in an in vitro dissolution test and exhibits considerable advantages in pharmacokinetics in vivo, showing a greater degree (AUC) and rate (C.sub.max) of drug absorption. Further provided by the present invention is a method for preparing an instant release pharmaceutical preparation of an anticoagulant; according to the formulation of the drug-containing particles as disclosed by the present invention, a capsule or tablet instant release preparation having excellent stability may be obtained by means of a combination of optional preparation steps.

The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of autosomal dominant polycystic kidney disease (ADPKD).

The invention relates to the use of a thienopyridone derivative, or a pharmaceutical composition comprising the same, in the treatment of autosomal dominant polycystic kidney disease (ADPKD).

A method of preventing, inhibiting or reducing cytokine release and the incidence of a cytokine release syndrome (CRS) or a cytokine storm in a subject with certain oxathiazin-like compounds and/or related compounds.

A method of preventing, inhibiting or reducing cytokine release and the incidence of a cytokine release syndrome (CRS) or a cytokine storm in a subject with certain oxathiazin-like compounds and/or related compounds.

The present invention provides for a method to treat pancreatic cancer. In various embodiments the method provides for administering one or more MAPK one or more MAPK pathway inhibitors to the subject, wherein the subject has a mutation in one or more genes in the MAPK signaling pathway.

The present invention provides for a method to treat pancreatic cancer. In various embodiments the method provides for administering one or more MAPK one or more MAPK pathway inhibitors to the subject, wherein the subject has a mutation in one or more genes in the MAPK signaling pathway.

In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an inhibitor of bromodomain (BRD) protein.

In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an inhibitor of bromodomain (BRD) protein.

The invention provides a compound of Formula I, ##STR00001##
Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.